We are evaluating the safety and optimal dosing of ABBV-383 for individuals with relapsed or refractory multiple myeloma. This study aims to improve treatment options for this challenging condition.
Health conditions and diseases that the clinical trial is designed to study and treat.
Relapsed or Refractory Multiple Myeloma is a type of blood cancer that occurs when multiple myeloma returns after treatment or does not respond to initial therapies. It can lead to symptoms such as bone pain, fatigue, and anemia.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
